Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00668967 · ClinicalTrials.gov registry record · Phase 1

Bioequivalence Study Of Verapamil

A Phase 1 study of Healthy Volunteers, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
79
Enrollment target
1
Study location

NCT00668967 is a Phase 1 study of Healthy Volunteers that has completed, run by Pfizer. The registered enrollment target is 79 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00668967, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
79 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to demonstrate bioequivalence of single doses of two verapamil formulations

Conditions Studied

Interventions

  • DRUG verapamil

Study Locations (1)

Connecticut

  • Pfizer Investigational Site - New Haven

Trial Details

FieldValue
Enrollment Target 79 participants
Start Date 2008-02
Est. Completion 2008-07
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00668967

The ClinicalTrials.gov registry entry for NCT00668967 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (84% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which verapamil is the first listed.

NCT00668967 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT00668967 about?

NCT00668967 is a clinical study titled "Bioequivalence Study Of Verapamil". The purpose of this study is to demonstrate bioequivalence of single doses of two verapamil formulations

What is the current status of trial NCT00668967?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2008-02. Estimated completion is 2008-07.

What conditions does trial NCT00668967 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT00668967?

The interventions under investigation include: verapamil (DRUG).

Who is sponsoring clinical trial NCT00668967?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00668967 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.